All In Biotech

Drug Trial Radar · NCT04166721

WaKING: Wnt and checKpoint INhibition in Gastric Cancer

A Multicenter Phase II Non-randomised Trial Assessing the Efficacy of DKN-01 Plus Atezolizumab in Patients With Advanced Mismatch Repair Proficient Oesophagogastric Cancer

Last checked: Nov 19, 2026Latest source record: Apr 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

52

Planned (sponsor's estimate)

Start

Feb 11, 2020

Primary completion

Mar 30, 2025

Study completion Dec 31, 2025

Sponsor

Lead sponsor
Royal Marsden NHS Foundation TrustAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 18, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicentre open-label non-randomised, Single Stage Ahern Design (with a 3+3 design for the safety run-in) phase II clinical trial of DKN-01 plus atezolizumab in patients with advanced unresectable or metastatic OGA who have progressed following chemotherapy.

Conditions

  • Metastatic Esophageal Cancer
  • Metastatic Gastric Cancer

Interventions

  • AtezolizumabDrug

    Immunotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety run-in phase: To recommend a safe and tolerable dose of combination DKN-01 and atezolizumab for use in the main (Phase IIB efficacy) phase of this trial.Time frame: The DLT period is 28 days from the start of the combination of DKN-01 and atezolizumab for any given patient (i.e. from C2 D1)
  2. Main phase IIB (efficacy) phase: Best objective response rate (ORR) using RECIST 1.1 criteriaTime frame: 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Royal Marsden NHS Foundation Trust

    Sutton, Surrey, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.